Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
NCT05764265
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
31
Enrollment
INDUSTRY
Sponsor class
Stopped
Sponsor Decision
Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG:
LTP001
Sponsor
Novartis Pharmaceuticals